French drugmaker Ipsen (Euronext: IPSEY) on Friday announced the appointment of Dr Alexandre Lebeaut as executive vice-president, R&D, and chief scientific officer, effective immediately.
Dr Lebeaut will report directly to David Meek, chief executive of Ipsen, and serve on the executive leadership team. Dr Lebeaut joined Ipsen in 2013 as senior VP, chief development officer, global drug development and was appointed Interim Head of R&D in December 2016.
Mr Meek commented: “It is my great pleasure to appoint Dr Lebeaut to lead Ipsen’s R&D organization. He brings outstanding medical and leadership experience from global pharmaceutical and biotechnology companies. Dr Lebeaut has consistently demonstrated an unwavering commitment to innovation, collaboration and successful execution of drug development strategies. During his four years at Ipsen, Dr Lebeaut has been instrumental in successfully leading our global development programs. He played a key role in the approval of Somatuline [lanreotide] for the treatment of neuroendocrine tumors, our partnership with Exelixis for Cabometyx [cabozantinib] and the acquisition of Onivyde [irinotecan]. He will continue to lead the transformation of Ipsen’s R&D strategy to further build a differentiated and sustainable portfolio to continue to address unmet medical needs in our key areas of expertise.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze